Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378701 · ClinicalTrials.gov registry record
Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 102
- Enrollment target
NCT02378701: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02378701 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02378701 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The goal of this research study is to test a quality-of-life questionnaire called QUALMS-1 in patients with MDS. This is an investigational study. Up to 240 participants will be enrolled in this multicenter study. Up to 175 will take part at MD Anderson.
Primary Outcome
Participants rate any change in their quality of life since enrollment using a 7-point Likert-type change rating scale, ranging from much better, to no change, to much worse. This change rating scale used to characterize the QUALMS-1's reliability compared to its first administration as well as its responsiveness.
Interventions
- BEHAVIORAL QUALMS-1 Questionnaire
- BEHAVIORAL FACT-An Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2015-02 |
| Est. Completion | 2022-07-18 |
What the finished NCT02378701 record still lists
NCT02378701 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which QUALMS-1 Questionnaire is the first listed.
NCT02378701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02378701 about?
NCT02378701 is a clinical study titled "Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease". The goal of this research study is to test a quality-of-life questionnaire called QUALMS-1 in patients with MDS. This is an investigational study. Up to 240 participants will be enrolled in this multicenter study. Up to 175 will take part at MD Anderson.
What is the current status of trial NCT02378701?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2015-02. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT02378701?
The interventions under investigation include: QUALMS-1 Questionnaire (BEHAVIORAL), FACT-An Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02378701?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia